Study #2004-0223
PHASE II STUDY OF 2-CHLORODEOXYADENOSINE (2CDA) FOLLOWED BY RITUXIMAB IN HAIRY CELL LEUKEMIA
Study Status
Open
Treatment Agent
2-Chlorodeoxyadenosine, Rituximab
Principal Investigator
Farhad Ravandi-Kashani
Description
The goal of this clinical research study is to learn if treatment with 2CDA (cladribine) followed by treatment with rituximab can help to control HCL. The safety of this combination treatment will also be studied.
General Information
Disease Group: Leukemia
Treatment Agent: 2-Chlorodeoxyadenosine, Rituximab
Treatment Location: Only at MD Anderson
Estimatated Length of Stay in Houston: No hospitalization required.
Sponsor: N/A
Return Visit: Daily for 5 days, then weekly for 8 weeks then every three months for first year. Patients can receive their treatment locally after the first dose of both agents has been administered at M.D. Anderson.
Home Care: Patients can receive their 2CDA and Rituximab treatment locally after the first ;dose of both agents has been administered at M.D. Anderson.
Study Status
IRB Review and Approval Date: MAY 19,2004
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Phone Number: 800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
clinicaltrials.gov NCT No: NCT00412594
Links:
Information and next steps
Disease:
Leukemia
Study phase:
Phase II
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789